La vendita allo scoperto per Madrigal Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Madrigal Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Madrigal Pharmaceuticals (NASDAQ:MDGL) Azioni, Report sulle vendite allo scoperto

MADRIGAL PHARMACEUTICALS INC

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals Inc

Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) stock is trading higher Wednesday after the company announced better-than-expected second-quarter earnings on Tuesday after <a href="https://www.benzinga.com//node/45757644">the market closed</a>.
What To Know: The company reported adjusted earnings per share of 38 cents, beating the consensus estimate of 33 cents. In addition, Hewlett posted sales of $7.63 billion, beating the consensus estimate of $7.50 billion, and representing a 6% year-over-year climb.
The company provided a breakdown of its revenue, noting that Server revenue grew 6% year-over-year to $4.1 billion, Intelligent Edge sales rose 7% year-over-year to $1.2 billion, Hybrid Cloud revenue increased 13% to $1.5 billion and Financial Services revenue slipped 1.3% to $856 million.
Outlook: The company sees third-quarter adjusted earnings per share from 40 cents to 45 cents, versus the consensus estimate of 56 cents. Furthermore, Hewlett expects sales from $8.20 billion to $8.50 billion, versus the consensus estimate of $8.85 billion.
Hewlett now expects fiscal-year 2025 adjusted earnings per share from $1.78 to $1.90, versus the consensus estimate of $1.79. It previously anticipated adjusted earnings per share from $1.70 to $1.90.
Marie Myers, executive vice president and CFO of Hewlett, said, &#8220;We are maintaining our focus on achieving efficiencies and streamlining operations across our businesses to position HPE for the future and deliver financial results aligned with our fiscal 2025&nbsp;outlook.&#8221;
Analyst Changes: Following the earnings report, multiple analysts raised their price targets. 
<ul class="wp-block-list">
<li>Barclays analyst Tim Long maintained an Overweight rating on Hewlett and raised the price target from&nbsp;$20&nbsp;to&nbsp;$24.</li>
<li>Wells Fargo analyst Aaron Rakers maintained an Equal-Weight rating on Hewlett Packard and raised the price target from&nbsp;$17&nbsp;to&nbsp;$20.</li>
<li>UBS analyst David Vogt maintained a Neutral rating on Hewlett and raised the price target from&nbsp;$16&nbsp;to&nbsp;$18.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/markets/large-cap/25/06/45775858/unitedhealth-board-reelects-directors-hikes-dividend-as-ceo-pledges-review-of-medicare-practices">UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices</a>
HPE Price Action: At the time of writing, Hewlett stock is trading 0.73% higher at $17.82, per data from Benzinga Pro.
Image: via Shutterstock

News

Movers

Hewlett Packard Stock Is Trading Higher Wednesday: What's Going On?

<a href="https://www.reuters.com/business/aerospace-defense/us-faa-not-currently-considering-lifting-boeing-737-max-production-cap-official-2025-06-04/" title="https://www.reuters.com/business/aerospace-defense/us-faa-not-currently-considering-lifting-boeing-737-max-production-cap-official-2025-06-04/">https://www.reuters.com/business/aerospace-defense/us-faa-not-currently-considering-lifting-boeing-737-max-production-cap-official-2025-06-04/</a>

UPDATE: "U.S. FAA Not Currently Considering Lifting Boeing 737 Max Production Cap, Official Says" - Reuters News

<a href="https://truthsocial.com/@realDonaldTrump/posts/114626083142393611">https://truthsocial.com/@realDonaldTrump/posts/114626083142393611</a>

General

President Trump Says Just Spoke With Putin; Says Call Was One Hour Fifteen Minutes; Says Discussed Ukraine Attack on Russia; Says Discussed Iran; Says Putin Will Participate in Discussions With Iran; Says Iran Slow-walking Decision on Nuclear Deal; Says Putin Conversation Was Good but Will Not Immediately Lead to Peace

WIIM

Novagold Resources shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $5 to $7.

AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares are rising Wednesday. Scotiabank speculated in a note to clients that Amazon&#8217;s Jeff Bezos could become an investor in the company, which appears to be pushing shares higher. Here&#8217;s what <a href="https://www.benzinga.com/quote/ASTS/analyst-ratings">you need to know</a>.
What To Know: Scotiabank analyst Andres Coello highlighted a recent Instagram <a href="https://www.google.com/imgres?imgurl=https://pbs.twimg.com/media/GshYMybWYAA5BY0?format%3Djpg%26name%3Dlarge&amp;tbnid=t1MPtoa6nymgdM&amp;vet=1&amp;imgrefurl=https://x.com/spaceinvestor_d&amp;docid=rySg8dcUCeTQJM&amp;w=1150&amp;h=2048&amp;source=sh/x/im/m1/1&amp;kgs=91c8da493df74929">post</a> from AST SpaceMobile board member Adriana Cisneros showing her in a photo with Bezos and AST SpaceMobile CEO Abel Avellan.
The post stated that &#8220;Amazing things are happening at AST &amp; Science + @blueorigin.&#8221; Coello noted that Avellan and Cisneros were wearing guest badges, while Bezos was not. The analyst also added that Blue Origin&#8217;s management team visited the AST SpaceMobile headquarters a few days before.
AST SpaceMobile is one of Blue Origin&#8217;s top customers after they teamed up in November last year for the launch of up to 45 BB2 satellites. The company&#8217;s agreement is featured on the Blue Origin website as one of the company&#8217;s top-three recent developments, which Coello believes suggests Blue Origin views AST SpaceMobile as a &#8220;leading player.&#8221;
&#8220;We doubt this was the sole reason why Mr. Bezos met with Avellan. There are major areas of opportunity where they could collaborate, particularly regarding Amazon's Project Kuiper, which intends to address the fixed broadband opportunity,&#8221; the Scotiabank analyst said. 
See Also: <a href="https://www.benzinga.com/news/space/25/06/45764046/elon-musk-dismisses-reports-that-spacex-is-valued-at-480-billion-says-it-sounds-too-high-predicts-its-revenue-will-exceed-nasas-budget-in-2026">Elon Musk Dismisses Reports That SpaceX Is Valued At $480 Billion, Says It Sounds &#8216;Too High:&#8217; Predicts Its Revenue Will Exceed NASA&#8217;s Budget In 2026</a>
Coello also suggested that Bezos could become an investor in AST SpaceMobile given the company&#8217;s positioning in the specialized RF technology space. AST SpaceMobile has thousands of patents, which creates a &#8220;formidable barrier to entry&#8221; for newcomers, including Kuiper.
&#8220;While Amazon intends to invest US$13B to US$16B in the Kuiper constellation of 3,236 satellites, the current market capitalization of ASTS stands at only US$8.3B,&#8221; Costello said, suggesting a potential tie-up between the companies on a larger scale.
&#8220;In summary, we wouldn't be surprised if both groups are exploring a larger agreement that could involve New Glenn's support for BB2 launches and possible commercial/equity agreements between ASTS and Amazon in order to address the global satellite fixed-wireless opportunity.&#8221;
Scotiabank has a <a href="https://www.benzinga.com/quote/ASTS/analyst-ratings">Sector Outperform rating</a> on AST SpaceMobile with a 12-month price target of $45.40.
ASTS Price Action: AST SpaceMobile shares climbed more than 4% on Tuesday as the Instagram post surfaced across various social platforms. The stock was up another 8.77% at $27.42 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a></li>
</ul>
Photo: hakanyalicn/Shutterstock.

Analyst Color

ASTS

AST SpaceMobile Stock Climbs After Analyst Flags Potential Investment From Amazon's Jeff Bezos

Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) has outperformed the market over the past 15 years by 2.54% on an annualized basis producing an average annual return of 14.52%. Currently, Analog Devices has a market capitalization of $108.72 billion. 
Buying $1000 In ADI: If an investor had bought $1000 of ADI stock 15 years ago, it would be worth $7,847.15 today based on a price of $219.08 for ADI at the time of writing.
<h3>Analog Devices's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749055534_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Securities Purchase Agreements
&nbsp;
On May 29, 2025 (the "Execution Date"), Mullen Automotive Inc. (the "Company") entered into two securities purchase agreements (each, a "Securities Purchase Agreement" and together, the "Securities Purchase Agreements"), with certain investors, pursuant to which upon the terms and subject to the conditions contained therein, the investors agreed to purchase upon execution 5% Original Issue Discount Secured Notes (the "Notes") convertible into shares of common stock, par value $0.001 per share (the "Common Stock"), and five-year warrants exercisable for shares of Common Stock (the "Warrants"). Pursuant to the first securities purchase agreement, the Company issued Notes in the aggregate principal amount of approximately $11.6 million and Warrants exercisable on a cash basis for 1,654,135 shares of Common Stock (the "$11M SPA"). Pursuant to the second securities purchase agreement, the Company issued Notes in the aggregate principal amount of approximately $2.8 million and Warrants exercisable on a cash basis for 387,969 shares of Common Stock (the "$2.8M SPA"). Unless stated otherwise, share amounts and prices are adjusted to reflect the 1:100 reverse stock split effected on June 2, 2025, and the terms summarized below apply to each Securities Purchase Agreement.

MULN

Reported Earlier: Mullen Automotive Enters $14.4M In Securities Purchase Agreements Including 5% Discount Convertible Notes And 5-Year Warrants For Over 2M Shares Following 1:100 Reverse Stock Split

Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock is trading higher on Wednesday.
As per data from Benzinga Pro, session volume stands at 31.74 million versus an <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">average volume of 674.72k</a>.
What Happened: The medical device and pharmaceutical packaging company initiated shipments for previously announced purchase orders across <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45766676/sharps-technology-begins-shipments-across-three-customer-orders-under-previously-announced-purchas" rel="noreferrer noopener">three customer orders</a>.
These shipments mark the company&#8217;s first deliveries of its SecureGard and SoloGard product lines and its transition to generating commercial revenue.
&#8220;These initial shipments mark a key operational milestone as Sharps officially transitions to a commercial-stage company,&#8221; stated Robert Hayes, CEO of Sharps Technology.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39647243/whats-going-on-with-nano-cap-medical-device-focused-sharps-technology-on-friday" rel="noreferrer noopener">What&#8217;s Going On With Nano-Cap Medical Device-Focused Sharps Technology On Friday?</a>
<h1 class="wp-block-heading">SoloGard Shipment</h1>
Sharps has initiated shipment of its first commercial order of SoloGard under a previously announced $50 million supply agreement with a U.S.-based leader in <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">IV flushing solutions</a>.
The delivery includes customized 10ml SoloGard smart safety syringes manufactured at the company&#8217;s upgraded facility in Hungary.
SoloGard is a smart safety syringe featuring ultra-low waste design, standard luer lock compatibility and re-use prevention technology.
This inaugural $400,000 purchase order marks the beginning of a five-year contract to supply up to 500 million syringes and represents the first revenue-generating shipment under the strategic supply agreement.
SoloGard&#8217;s manufacturing is supported by advanced molding and automation technologies recently invested in by the company, enabling Sharps to meet the anticipated increase in demand under the agreement during the second half of 2025.
<h1 class="wp-block-heading">SecureGard Shipment</h1>
Sharps delivered SecureGard smart safety syringes in a separate shipment to a Hungarian vaccine provider following a $100,000 purchase order.
SecureGard is a safety syringe featuring an integrated active recessed safety system, ultra-low waste design and re-use prevention technology.
Combined with the SoloGard order, total purchase commitments reached approximately $500,000, establishing Sharps as a revenue-producing company and supporting its transition to commercial operations.
<h1 class="wp-block-heading">Additional Shipment</h1>
Additionally, Sharps has commenced shipment of 200,000 units of 1ml low-dead space syringes to a Swiss-based global provider of cosmetic, dental and ophthalmic injectable therapies.
The syringes will be used in a specialized injection pen to deliver Botox and represent the first tranche of a 1-million-unit order.
STSS Price Action: STSS stock is up 60.60% at $6.01 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45770679/alibaba-jd-see-sales-soar-in-618-festival-apple-and-xiaomi-emerge-as-top-selling-brands" target="_blank" rel="noreferrer noopener">Alibaba, JD See Sales Soar In 618 Festival, Apple And Xiaomi Emerge As Top Selling Brands</a></li>
</ul>
Photo: solarseven via Shutterstock

Biotech

Health Care

STSS

Why Is Sharps Technology Stock Soaring On Wednesday?

Cellectar Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock is trading higher on Wednesday.
As per data from Benzinga Pro, session volume stands at 361.96 million versus an <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">average volume of 968.03k</a>.
What Happened: The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation on Wednesday for the company&#8217;s iopofosine I 131, a potential first-in-class, novel cancer-targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for relapsed/refractory Waldenstrom <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">macroglobulinemia (r/r WM)</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/12/42442003/cellectar-biosciences-stock-plunges-as-cancer-focused-cancer-firm-pursues-strategic-options" target="_blank" rel="noreferrer noopener">Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options</a>
Why It Matters: WM is the dominant subtype of lymphoplasmacytic lymphoma.
Data from the Phase 2 CLOVER WaM study, including the overall response rate (ORR) of 83.6% and a major response rate (MRR) of 58.2%, which exceeded the agreed-upon primary endpoint of a 20% MRR, were presented during the 66th Annual American Society of Hematology Conference in December 2024.
As previously announced, the FDA also granted iopofosine I 131 Fast Track Designation <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45768008/cellectar-granted-u-s-fda-breakthrough-therapy-designation-for-iopofosine-i-131-in-waldenstrom-mac" rel="noreferrer noopener">and Orphan Drug Designation</a>.
The European Medicines Agency (EMA) granted Orphan Drug Designation to iopofosine I&nbsp;131 for r/r WM and PRIME Designation for WM.
What&#8217;s Next: Separately, the company has provided the EMA with a data package that includes extensive supportive preclinical, regulatory, and manufacturing data and safety and efficacy data from the CLOVER WaM Phase 2b clinical trial.
The EMA will review the package to determine whether there is enough clinical evidence to address the required criteria for Cellectar to apply for a fast-track, conditional marketing authorization approval.
In late July 2025, the company expects a recommendation from the EMA on whether Cellectar should file a Medical Authorization Application.
Price Action: CLRB stock is trading higher by 57.9% to $0.43 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/small-cap/25/06/45770622/sprinklr-rises-on-solid-earnings-raised-outlook-and-new-150-million-buyback-plan" target="_blank" rel="noreferrer noopener">Sprinklr Rises On Solid Earnings, Raised Outlook, And New $150 Million Buyback Plan</a></li>
</ul>
Photo by Tada Images via Shutterstock

CLRB

What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained

ONEOK shares are trading lower after the company acquired the remaining shares of Basin JV for $940 million. Additionally, Barclays cut its price target on the stock from $101 to $91.

<a href="https://www.bloomberg.com/news/articles/2025-06-04/trump-tariffs-carney-holds-back-on-retaliation-says-us-talks-are-progressing">https://www.bloomberg.com/news/articles/2025-06-04/trump-tariffs-carney-holds-back-on-retaliation-says-us-talks-are-progressing</a>

'Carney Holds Back on Tariff Retaliation, Says US-Canada Talks Are Progressing'- Bloomberg

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 5.23% on an annualized basis producing an average annual return of 17.22%. Currently, Verisk Analytics has a market capitalization of $44.41 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $1,103.04 today based on a price of $317.51 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749054696_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

Here's How Much You Would Have Made Owning Verisk Analytics Stock In The Last 15 Years

HOTH

Hoth Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 25%

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1535527/000153552725000019/crwd-20250430.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1535527/000153552725000019/crwd-20250430.htm</a>

CRWD

Crowdstrike Has Received Requests From DOJ, SEC for Information Relating to the Company's Recognition of Revenue and Reporting of ARR for Transactions With Certain Customers, the July 19 Incident and Related Matters

Thor Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) shares are trading higher on Wednesday after the company reported third-quarter EPS of $2.53 <a href="https://www.benzinga.com/earnings">beating the street consensus of $1.83</a>.
Quarterly sales of&nbsp;$2.89 billion, up 3.3%&nbsp;year over year (Y/Y), outpaced the analyst <a href="https://www.benzinga.com/pressreleases/25/06/g45766242/thor-industries-announces-third-quarter-fiscal-2025-results" target="_blank" rel="noreferrer noopener">consensus estimate of&nbsp;$2.48 billion</a>.
Gross profit margin in the quarter under review expanded by 20 basis points year over year to&nbsp;15.3%.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs" rel="noreferrer noopener">Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs</a>
Adjusted EBITDA increased 7.9%&nbsp;Y/Y to&nbsp;$254.8 million in the quarter.
North American Towable Recreational Vehicle (RV) net sales increased&nbsp;9.1% Y/Y, while North American Motorized RV net sales rose 3.1%&nbsp;Y/Y in the quarter.
North American Towable RV net sales benefitted from 5.5% higher unit shipments and a 3.6% increase in net price per unit. 
Gross profit margin improved 200 basis points to 14.9%, attributed to higher sales, less discounting, better warranty costs, and ongoing savings.
North American Motorized RV net sales increased due to a 10.9% rise in unit shipments (partly from promotions), though a 7.8% decrease in net price per unit (due to product mix shift and higher discounting) partially offset this. 
Gross profit margin fell to 10.5% from 11.1%, primarily owing to increased sales discounting.
As of April 30, the order backlog for North American Towable RV stood at $634.3 million (-14.4%) and North American Motorized RV came in at $883.7 million (-4.5%).
European RV net sales decreased&nbsp;5.1% Y/Y&nbsp;for the&nbsp;quarter, led by a&nbsp;12.2%&nbsp;decrease in unit shipments, which was offset in part by a&nbsp;7.1% Y/Y&nbsp;increase in the overall net price per unit.&nbsp;
European RV net sales fell due to a 12.2% drop in unit shipments, partially offset by a 7.1% increase in net price per unit. The price increase included a 6.8% rise from product mix and pricing changes, plus a 0.3% benefit from foreign currency exchange rates.
European RV gross profit margin contracted 130 basis points to 16.2% on increased sales discounting.
As of&nbsp;April 30, the order backlog for European RV came in at $1.34 billion (-30.6%).
The company exited the quarter with cash and cash equivalents worth&nbsp;$508.3 million, with net inventories worth&nbsp;$1.35 billion. Long-term debt (net) at the end of the quarter stood at $1.01 billion.
Todd Woelfer, senior VP and COO, said, &#8221;As we anticipated and messaged at the beginning of our fiscal year, our North American Motorized and European segments have both seen year-over-year declines in gross margin but still achieved resilient results considering the challenging environments facing those segments.&#8221; 
&#8221;While our consolidated margin this quarter was unfavorably impacted by actions we took to deepen our partnerships with key dealers, strategically, deepening these key relationships is vital to our long-term market position and these decisions favorably position THOR for the future as we look ahead,&#8221;
Thor Industries reaffirmed its FY25 EPS guidance of $3.30 to $4.00 compared <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">to analyst estimates of $3.59</a>.
The company also maintained its FY25 sales guidance at $9.00 billion to $9.50 billion versus the <a target="_blank" href="https://www.benzinga.com//node/44139488" rel="noreferrer noopener">analyst estimate of $9.25 billion</a>.
Bob Martin, president and CEO, added, &#8221;Our financial guidance assumed a stronger second half of our fiscal year, and our fiscal third quarter performance reflects the value of our strategies in the currently difficult market.&#8221;
&#8221;We expect the fourth quarter of our fiscal 2025 and the first quarter of our fiscal 2026 to be challenging. The current economic uncertainty has led to downward pressure on consumer confidence and has negatively impacted retail pull-through. We believe that upon the resolution of this uncertainty, we will see improved consumer confidence and the return of a strong retail environment,&#8221; he added.
Year-to-date, the stock has declined around 11%. The short float for Thor Industries is 18.33%, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Price Action: THO shares are trading higher by 3.44% to $85.25 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45765484/dow-futures-edge-higher-after-two-days-of-gains-expert-says-trump-tariffs-distorting-pretty-much-everything" target="_blank" rel="noreferrer noopener">Dow Futures Edge Higher After Two Days Of Gains: Expert Says Trump Tariffs &#8216;Distorting Pretty Much Everything&#8217;</a></li>
</ul>
Image by Michael Gordon via Shutterstock

Earnings

Guidance

Recreational Vehicle Maker Thor's European Sales Hit By Dip, Cautions On Macro Outlook

Analyst Ratings

MSFT

Live On CNBC, Jim Lebenthal Announced Trimmed Microsoft

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang highlighted the company's role in helping boost the new features of <a href="https://www.benzinga.com/general/gaming/25/04/44609298/nintendo-switch-2-price-release-date-specs-new-games-revealed">the highly anticipated</a><a href="https://www.benzinga.com/general/gaming/25/04/44609298/nintendo-switch-2-price-release-date-specs-new-games-revealed"> </a>Nintendo Switch 2 gaming console from Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) in a recent video.
What Happened: Nintendo stock has soared in 2025 ahead of the June 5 release of the Switch 2, a handheld video game console that follows up the highly successful Nintendo Switch released in 2017.
"It brings together three breakthroughs: the most advanced graphics ever in a mobile device, full hardware ray tracing, high dynamic range for brighter highlights and deeper shadows and an architecture that supports backward compatibility," Huang said in a video <a href="https://x.com/NintendoAmerica/status/1929886108113932624">shared </a>by Nintendo.
Huang said the Nvidia chip inside the Switch 2 is "unlike anything we've built before," as <a href="https://www.cnbc.com/amp/2025/06/03/nintendo-switch-2-ai-nvidia.html">reported</a> by CNBC.
The Nvidia CEO said the Switch 2 has dedicated artificial intelligence processors that will help to "sharpen, animate and enhance gameplay in real time."
"Switch 2 is more than a new console. It's a new chapter worthy of Iwata-san's vision."
Huang's comments paid tribute to former Nintendo CEO Satoru Iwata, who passed away in 2015 before the first Switch was released. Iwata worked on the concept of the original Switch.
Read Also:<a href="https://www.benzinga.com/news/education/25/05/45701924/jensen-huang-founded-nvidia-at-a-dennys-now-hes-worth-600x-more-than-the-restaurant-chain"> Jensen Huang Founded Nvidia At A Denny&#8217;s, Now He&#8217;s Worth 600x More Than The Restaurant Chain</a>
Why It's Important: The Nintendo Switch 2 will be released on June 5 and comes with a suggested retail price of $449.99 for the U.S. market.
The console is the first from Nintendo in eight years and comes with new features that have gamers excited to get their hands on devices as soon as possible.
Nintendo expects to sell 15 million Switch 2 consoles in the current fiscal year, as <a href="https://www.cnbc.com/video/2025/05/08/nintendo-expects-to-sell-15-million-units-of-the-switch-2.html">reported </a>by CNBC. The console will likely help boost Nintendo's financials and could send shares higher with strong early sales figures and high demand.
Nvidia stock could also get a small boost. While the Gaming &amp; AI PC division for Nvidia is smaller than its Data Center business, the segment saw first-quarter revenue of $3.8 billion, which was up 42% year-over-year.
The gaming segment saw revenue jump 48% quarter-over-quarter in the first quarter, the highest sequential growth of any Nvidia segment.
Nvidia highlighted its products being used for the Nintendo Switch 2 during the earnings report. The big question will be how much of the revenue is already baked into the segment versus potential upside from more devices sold in future quarters or demand quickly outpacing supply.
Price Action: Nvidia stock is down 0.24% at $140.89 on Wednesday versus a 52-week trading range of $86.63 to $153.13. Nvidia stock is up 2.1% year-to-date in 2025.
Nintendo stock is up 2.40% at $20.93 on Wednesday versus a 52-week trading range of $11.36 to $22.08. Nintendo stock is up 42.9% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong">Nvidia Q1 Highlights: China Export Ban Hits Results But Jensen Huang Says Demand &#8216;Incredibly Strong&#8217;</a></li>
</ul>
Photo: Shutterstock

Gaming

Long Ideas

Management

Tech

NTDOY

NVDA

Jensen Huang Says Nintendo Switch 2 Has AI Processors To Enhance Gameplay: 'Unlike Anything We've Built Before'

JPMorgan analyst Mark R Murphy <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings" target="_blank" rel="noreferrer noopener">reiterated an Overweight</a> rating on Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a price target of $225 on Wednesday.
Murphy attended Snowflake&#8217;s Investor Day presentation in San Francisco, in conjunction with its annual Summit conference. Snowflake&#8217;s Investor Day presentation primarily focuses on its product and technology roadmap as it lays out an expansive strategic vision for the data cloud in the era of AI, the analyst said.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45623498/snowflakes-ai-driven-insights-to-power-la28-olympic-and-paralympic-games" rel="noreferrer noopener">Snowflake&#8217;s AI-Driven Insights To Power LA28 Olympic And Paralympic Games</a>
A financial section was absent from the Investor Day presentation, an understandable dynamic as Snowflake continues its process to select a new CFO after current CFO Mike Scarpelli&#8216;s planned retirement, he said.
Despite the lack of explicit financial guidance or macro-demand update, Murphy noted Snowflake is striking a confident tone overall as it begins to realize benefits from the product, go-to-market (GTM), and other operational initiatives it has undertaken or accelerated since Sridhar Ramaswamy was elevated to CEO in February 2024.
Net-net, the analyst came away incrementally positive following the Investor Day and the relatively upbeat nature of his conversations thus far with partners and customers regarding Snowflake.
Recently-appointed CRO Mike Gannon provided an overview of Snowflake&#8217;s Go-To-Market organization and stated that Snowflake hired over 500 sales and marketing folks in the first quarter. While the 500 additional S&amp;M heads is a gross figure, Murphy noted the hiring scale is notable, particularly as hiring activity across many other software companies has been relatively more muted, and likely reflects the opportunity Snowflake is seeing in the market.
Snowflake discussed ongoing industry adoption of the Iceberg data formats, noting that open data table formats like Iceberg make it easier for customers to switch between different data processing engines. As a result, the analyst noted that Snowflake said that customers will move toward the data platforms that offer the most value.
For Snowflake, Iceberg is experiencing a dynamic wherein the tailwinds and opportunity it provides &#8220;far exceed and outpace the potential headwinds,&#8221; he said.
When asked about its view on more and more SaaS companies moving into the data layer, Murphy said that Snowflake suggested that this move is driven by AI as the rise of Agents is potentially impacting the traditional SaaS model.
However, Snowflake noted that it has a bidirectional data-sharing dynamic with many leading SaaS companies and that the relationships are mutually beneficial.
Snowflake built on its vision of the AI Data Cloud through a series of product unveilings. These announcements included Openflow, Gen2, Adaptive Compute, Intelligence, Snowflake Data Science Agent, and Cortex AISQL.
Murphy is encouraged by Snowflake&#8217;s slate of new products and the recent increased pace of innovation.
In the long term, the analyst noted that Snowflake is benefiting from demonstrable secular tailwinds, supported both qualitatively and quantitatively by his CIO Survey and partner checks. He continues to be impressed by the company&#8217;s accelerated pace of product innovation, including around AI/ML. 
Murphy noted favorable competitive positioning in the longer term as the data layer increasingly gains control over AI.
The analyst projected second-quarter revenue of $1.08 billion and adjusted EPS of $0.25.
Price Action: SNOW stock is trading higher by 1% to $211.24 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45755544/rising-ai-analytics-budgets-could-lift-microsoft-snowflake-datadog" target="_blank" rel="noreferrer noopener">Rising AI, Analytics Budgets Could Lift Microsoft, Snowflake, Datadog</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

SNOW

Snowflake Just Hired 500 Sellers—Is This The Start Of A Full-Scale AI Land Grab?

CSCO

QCOM

Live On CNBC, Jim Lebenthal Announced Bought More Cisco; Bought More Qualcomm

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 5 years by 16.18% on an annualized basis producing an average annual return of 29.4%. Currently, Amphenol has a market capitalization of $111.72 billion. 
Buying $100 In APH: If an investor had bought $100 of APH stock 5 years ago, it would be worth $354.53 today based on a price of $92.25 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749053712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Amphenol 5 Years Ago Would Be Worth This Much Today

Press Releases

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Comments

Madrigal Pharmaceuticals

Vendite allo scoperto

Madrigal Pharmaceuticals (NASDAQ:MDGL) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO